Pharmacokinetics of Intra-Arterial Melphalan in Patients withRecurrent or Progressive Retinoblastoma Treated on Spog-Rb-2011, A NationalPhase II Study of the Swiss Paediatric Oncology Group by Diezi, Manuel et al.
S252 SIOP ABSTRACTS
P-0786 Eye Rescue in Patients with Retinoblastoma using Intravitreal
Chemotherapy Injection in a Tertiary Institution at Mexico. Preliminary Report
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Background/Objectives: Retinoblastoma is the most common primary intraocular malig-
nancy of infancy. Intravitreal chemotherapy is an eﬀective modality for treating intravitreal
disease. The purpose of this paper is to evaluate the eﬃcacy and safety of intravitreal injection
of melphalan for relapsed and refractory retinoblastoma in a period of two years (2014 -2016).
Design/Methods: This is a prospective cohort of patients with viable vitreous seeds of relapsed
and refractory retinoblastoma. The patients received injections of melphalan 30 휇g (range: 7-8
injections).
Results: All patients were at stage C (International Classification of Retinoblastoma). The
follow up was at the interval of 9-23 months (median: 16 months) and ocular status response
was classified in 3 groups: ocular rescue with active disease (n=1), ocular rescue with complete
response (n=8), and failure with enucleation (n=1). Successful control of vitreous seeds was
achieved in 8 of 10 patients. No one presented complications related to the procedure. There
was no local tumour spread.
Conclusion: Intravitreal chemotherapy with melphalan is an eﬀective treatment in patients
with vitreous seeds for eye rescue, actually standardized in developed and developing countries.
This treatment also avoids the use of radiotherapy with the known consequences.
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Background/Objectives: Since the 1990s, intravenous (iv) chemotherapy has been the system-
atic first-line treatment used in the management of retinoblastoma, to reduce tumour volume
and render it accessible to focal treatments as well as to avoid enucleation and/or radiother-
apy. This approach has allowed globe preservation in the majority of group A-C tumors and in
19-60% of group D cases. Relapse or tumour progression in this group D patients constitute a
major concern for globe salvage. Techniques of local administration of chemotherapy, such as
Selective Ophtalmic Artery Chemotherapy (SOAC) administration oﬀers an interesting alter-
native. We report here pharmacokinetic analysis of melphalan administered by SOAC in eight
patients, their clinical response to SOAC and observed toxicities.
Design/Methods: Monocentric single arm, phase II prospective non-randomized study.
Among included patients, plasma levels of Melphalan were determined by high-performance
liquid chromatography/tandemmass spectrometry (LC-MS/MS) at 0, 0.5, 1.5, 3, 4 and 24 hours
after unilateral SOAC administration of melphalan. Full blood counts were collected weekly.
Results: A total of 47 melphalan plasma concentrations from 8 consecutive patients were col-
lected. Each patient received between 1 to 3 SOAC. Mean administered dose was 0.33mg/kg
(SD: 0.05). Mean maximal concentration (Cmax) was 743 ng/ml (SD: 235) at 0.5 hour. Clear-
ance was calculated at 0.24 L/h/kg (SD: 0.05) and mono-compartemental volume of distri-
bution (Vd) was estimated at 0.27 L/kg (SD: 0.07). Six patient needed additional treatment.
Seven patients had a favourable (no enucleation, no radiotherapy) final outcome whereas 1 had
an enucleation. Two patients developed mild neutropenia (ANC 500-1000 G/L) 2 weeks after
the administration, without fever or infection.
Conclusion: We report pharmacokinetic parameters of melphalan administered by unilat-
eral SOAC in 8 patients. Whereas 6/8 patient needed additional treatment, final outcome was
favourable in the majority (7/8) of patients. Two patients developed a mild neutropenia which
did not seem to correlate with pharmacokinetic parameters.
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Background/Objectives: To outline eye salvage rates, patient survival and adverse events of
IAC for newly and relapsed retinoblastoma patients.
Design/Methods: Single institution retrospective review of all retinoblastoma patients treated
with IAC from 01/2012 to 03/2016. One to 5 cyles every 3 weeks of IAC with melphalan for
newly diagnosed patients or melphalan and topotecan for salvage treatment; with carboplatin
to all patients with no response or progression after 2 drugs. 20% were group C, 51% group D
and 13% group E. Local therapy as indicated between IAC, intravitreous was performed for all
patients with vitreous seeds. Primary outcome was eye retention without need for radiotherapy.
Toxicity was evaluated.
Results: Seventy one eyes (59 patients) that underwent IAC were included (average follow-
up was 4.3 months, range 1-18 months). 29 were newly diagnosed and 42 eyes received prior
treatment elsewhere. Median number of IAC cycles/eye as 3 (range 1-9). 71 eyes received intra-
arterial melphalan, alone in 7 eyes. 35 eyes received carboplatin and 64 received topotecan.
12 eyes received intravitreous carboplatin due to vitreous seeds. 12 eyes (8 pretreated and 4
newly diagnosed) failed treatment and required enucleation. Radiotherapy was avoided in all
cases. Toxicity Grade 3-4 (4 grade III and 8 grade IV) was more common in patients receiving
treatment bilaterally. No child died of metastatic disease.
Conclusion: IAC is eﬀective for treating retinoblastoma, achieving rates of eye salvage higher
than systemic chemotherapy even in eyes previously treated and with international classifi-
cation of retinoblastoma group D and E in most cases. It can be performed many times with
multiple agents on one or both eyes. IAC with or without intravitreous chemotherapy can avoid
external beam radiotherapy, reduced the use of systemic chemotherapy, and diminished enu-
cleations without evidence of compromising patient survival. Toxicity is very mild.
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Background/Objectives: Retinoblastoma is incurable in low income countries due to delayed
diagnosis and poor access to health care.
Aim: To determine the outcome of children treated with low cost chemotherapy according to
SIOP-PODC guidelines for low income countries.
Design/Methods: This is an interim analysis of 51 children recruited at Mbingo Baptist hospi-
tal, North-West Cameroon and treated with a modified treatment protocol for low income coun-
tries: surgery as indicated; Vincristine, Cyclophosphamide and Adriamycin on day 1 every 3-4
weeks if indicated. Ultrasound studies of the involved eye was done as other imaging studies
were not available.
Results: Three patients were excluded due to toxoplasmosis retinitis. The male to female ratio
was 1:1 and mean age 29 months (range 9 weeks -7 years). The majority (34%) had advanced
disease (stages 3 and 4), followed by 29% with stage 1, stage 2 and 5 respectively 8 and 6%,
stage 0 was 4%, and unknown stage in 19%. The left eye was most commonly involved (48%),
while 16% were bilateral. Ultrasound was done in 46% of patients to determine the extent of
disease prior to surgery and 73% had an enucleation done. The majority completed 6 cycles of
chemotherapy (48%), while 10% received only pre-operative chemotherapy for tumour shrink-
age before surgery and 10% were still on chemotherapy. A third are still alive, a third had died,
while the rest were either still on treatment or being traced for final outcome.
Conclusion:Not all intraocular disease is retinoblastoma and in tropical regions toxoplasmosis
must be excluded. Ultrasound may assist in determining extent of disease due to lacking of
other imaging modalities. Chemotherapy is feasible for more extensive disease, especially for
shrinking of large tumours prior to surgery. Final analysis will provide evidence for the eﬃcacy
of a modified treatment protocol.
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Background/Objectives: To describe the eﬃcacy of intravitreal chemotherapy (IViC) com-
bined with intra-arterial chemotherapy (IAC) for the treatment of advanced stage retinoblas-
toma.
Design/Methods: This non comparative interventional case series retrospectively reviewed
the medical records of ten patients who presented within months of each other with unilateral
advanced intraocular retinoblastoma, Reese-Ellsworth (R-E) stage Vb/D of ABC Classifica-
tion in the aﬀected eye. After clinical and ophthalmoscopic evaluation, they underwent MRI
to exclude local and CNS dissemination. The IAC was given to treat retinal masses and intrav-
itreal injections to treat vitreous seeding. Patients had received 2 cycles (six infusions) of IAC
(melphalan and topotecan), and from 6 up to 10 melphalan injections (20 휇g) into the vitreous.
No permanent complications of procedures have been reported. All patients underwent fundus
examination every three weeks and bimonthly MRI examination during treatment and every 3
months for 1 year after last injection, to exclude orbital dissemination.
Results: Successful control (100%) of tumour masses and vitreous seeds was achieved in all
cases at 12 months follow-up. Complications were posterior lens opacity, acute ischemic papil-
litis, partial CVR thrombosis, hypotonia (case 1), partial vitreous hemorrhage (case 4). No com-
plications appeared in cases 2, 3, 5 and 6,7,8,9,10. No intraocular or orbital tumour recurrence
or retinoblastoma metastases (follow-up range, 12 – 36 months) were observed.
Conclusion: Combined and alternated intra-arterial chemotherapy and intravitreal melphalan
for advanced retinoblastoma allowed to provide retinal and vitreous seed control.
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